This inventor holds 7 USPTO granted patents, plus 1 CIPO patent and 1 EPO patent. Top assignees: Takeda Pharmaceutical Company Limited, Takeda Chemical Industries, Inc.. Active years: 2001-2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:


Years Active: 2001-2024
Title: Koichiro Fukuoka: Innovator in Thienopyrimidine Derivatives
Introduction
Koichiro Fukuoka is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of thienopyrimidine derivatives. With a total of 7 patents to his name, Fukuoka's work has had a notable impact on medical science.
Latest Patents
Fukuoka's latest patents include innovative methods for producing thienopyrimidine derivatives that exhibit gonadotropin-releasing hormone (GnRH) antagonistic action. One of his key inventions provides a production method that ensures high quality and yield of these derivatives. The method involves the reaction of specific chemical compounds, including 6-(4-aminophenyl)-1-(2,6-difluorobenzyl)-5-dimethylaminomethyl-3-(6-methoxypyridazin-3-yl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione, along with 1,1'-carbonyldiimidazole and methoxyamine.
Career Highlights
Throughout his career, Fukuoka has worked with notable companies such as Takeda Pharmaceutical Company Limited and Takeda Chemical Industries, Inc. His experience in these organizations has allowed him to refine his expertise in pharmaceutical innovations.
Collaborations
Fukuoka has collaborated with esteemed colleagues, including Kazuhiro Miwa and Shokyo Miki. These partnerships have contributed to the advancement of his research and the successful development of his patented inventions.
Conclusion
Koichiro Fukuoka's contributions to the field of pharmaceuticals, particularly through his patents on thienopyrimidine derivatives, highlight his role as an influential inventor. His work continues to pave the way for advancements in medical treatments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile